Finance

Lists
ZBH:NYSE
Zimmer Biomet Holdings, Inc
89,14 $
+0,29%
(+0,26) 1D
89,00 $
-0,16% (-0,14)
After hours
Closed: 9 қаз., 16:00:06 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBH...
Open
88,93 $
High
90,21 $
Low
88,40 $
Mkt. cap
17,00 млрд
Avg. vol.
2,02 млн
Volume
1,60 млн
Dividend
1,08%
Quarterly dividend
0,24 $
Ex-dividend date
2026 ж. 30 қыр.
P/E ratio
21,70
52-wk high
106,88 $
52-wk low
79,12 $
EPS
4,11 $
Beta
0,48
Shares outstanding
190,74 млн
No. of employees
17 мың
Open
88,93 $
High
90,21 $
Low
88,40 $
Mkt. cap
17,00 млрд
Avg. vol.
2,02 млн
Volume
1,60 млн
Dividend
1,08%
Quarterly dividend
0,24 $
Ex-dividend date
2026 ж. 30 қыр.
P/E ratio
21,70
52-wk high
106,88 $
52-wk low
79,12 $
EPS
4,11 $
Beta
0,48
Shares outstanding
190,74 млн
No. of employees
17 мың
News stories
From web sources and news partners
Profile
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster. In 2001, Zimmer was spun off from Bristol Myers Squibb and began trading on the New York Stock Exchange, on August 7, under the ticker symbol “ZMH”. In November 2011, the company acquired ExtraOrtho, Inc. In January 2012, the company acquired Reno, Nevada-based Synvasive Technology, Inc. On June 29, 2015, the company changed the ticker symbol to "ZBH" to reflect its acquisition of Biomet. On January 12, 2017, Zimmer Biomet announced a resolution with the DOJ and the SEC in which it agreed to pay a fine of approximately $30.5 million, an amount which would not affect its 2017 outlook. Wikipedia
About Zimmer Biomet Holdings, Inc
CEOIvan Tornos
Employees17 мың
Founded1927
HeadquartersWarsaw, Индиана, Америка Құрама Штаттары
SectorMedical device
Analyst ratings
Based on 18 analysts giving stock ratings to ZBH in the past 3 months
Buy
Buy
5
Hold
13
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for ZBH in the last 3 months.
Highest
Current 89,14 $
120,00 $ (+34,62%)
Average
105,40 $ (+18,24%)
Lowest
93,00 $ (+4,33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Christopher Pasquale
Barclays
Hold
Initiated
100,00 $
+12,2%
10/07/2026
Matt Miksic
Barclays
Hold
Maintained
100,00 $
+12,2%
10/07/2026
Joanne Wuensch
Citi
Hold
Maintained
99,00 $
+11,1%
10/05/2026
Kendall Au
RBC Capital
Buy
Maintained
110,00 $
+23,4%
10/01/2026
Travis Steed
Bank of America Securities
Hold
Maintained
110,00 $
+23,4%
09/25/2026
Richard Newitter
Truist Financial
Hold
Reiterated
106,00 $
+18,9%
09/16/2026
Robbie Marcus
J.P. Morgan
Hold
Maintained
117,00 $
+31,3%
08/17/2026
Caitlin Roberts
Canaccord Genuity
Buy
Maintained
100,00 $
+12,2%
08/10/2026
Jeff Johnson
Robert W. Baird
Hold
Maintained
104,00 $
+16,7%
08/06/2026
Pito Chickering
Deutsche Bank
Hold
Maintained
98,00 $
+9,9%
08/06/2026
Steven Lichtman
William Blair
Hold
Maintained
-
-
08/06/2026
Patrick Wood
UBS
Buy
Maintained
120,00 $
+34,6%
08/06/2026
Lee Hambright
Bernstein
Hold
Maintained
93,00 $
+4,3%
08/06/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
110,00 $
+23,4%
08/06/2026
Vik Chopra
BMO Capital
Hold
Maintained
96,00 $
+7,7%
08/06/2026
Larry Biegelsen
Wells Fargo
Hold
Reiterated
103,00 $
+15,5%
08/06/2026
Michael Matson
Needham
Hold
Maintained
-
-
08/05/2026
Mathew Blackman
TD Cowen
Buy
Maintained
115,00 $
+29%
08/05/2026
Danielle Antalffy
UBS
Buy
Upgraded
115,00 $
+29%
07/28/2026
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
07/23/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
101,00 $
+13,3%
07/13/2026
Unknown Analyst
BMO Capital
Hold
Initiated
95,00 $
+6,6%
07/09/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
110,00 $
+23,4%
07/06/2026
Caitlin Cronin
Canaccord Genuity
Hold
Reiterated
83,00 $
-6,9%
04/29/2026
David Turkaly
Citizens JMP
Buy
Maintained
105,00 $
+17,8%
04/29/2026
Mike Kratky
Leerink Partners
Hold
Initiated
101,00 $
+13,3%
04/13/2026
David Roman
Goldman Sachs
Sell
Maintained
88,00 $
-1,3%
02/10/2026
Last report
2026 ж. 05 там.
Fiscal period
Q2 2026
2,07 $ / 2,01 $
+2,99%beat
Revenue / Est. (USD)
2,18 млрд / 2,14 млрд
+1,95%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
2,00 млрд
2,24 млрд
2,09 млрд
2,18 млрд
Cost of goods sold
559,30 млн
795,50 млн
594,20 млн
635,50 млн
Cost of revenue
559,30 млн
795,50 млн
594,20 млн
635,50 млн
Research and development expenses
115,90 млн
118,70 млн
103,40 млн
104,80 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
809,40 млн
838,50 млн
846,20 млн
882,30 млн
Operating expense
1,10 млрд
1,13 млрд
1,11 млрд
1,15 млрд
Total operating expenses
1,66 млрд
1,93 млрд
1,71 млрд
1,79 млрд
Operating income
340,30 млн
313,40 млн
380,80 млн
391,00 млн
Other non operating income
6,20 млн
15,10 млн
5,50 млн
6,00 млн
EBT including unusual items
279,20 млн
97,90 млн
301,30 млн
255,10 млн
EBT excluding unusual items
269,30 млн
250,00 млн
310,20 млн
320,80 млн
Income tax expense
48,00 млн
-39,90 млн
63,00 млн
55,50 млн
Effective tax rate
17,19%
-40,76%
20,91%
21,76%
Other operating expenses
-
-
-
-
Net income
230,90 млн
139,30 млн
238,10 млн
198,30 млн
Net profit margin
11,54%
6,21%
11,41%
9,11%
Earnings per share
1,90
2,42
2,09
2,07
Interest and investment income
-
-
-
-
Interest expense
-75,40 млн
-71,90 млн
-68,80 млн
-72,90 млн
Net interest expenses
-75,40 млн
-71,90 млн
-68,80 млн
-72,90 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
623,90 млн
597,40 млн
650,80 млн
661,80 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары